TCIM
CLVS

TIAA CREF Investment Management’s Clovis Oncology, Inc. CLVS Stock Holding History

TIAA CREF Investment Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$6.34M Buy
255,289
+90,604
+55% +$2.27M ﹤0.01% 1292
2018
Q4 		$2.96M Sell
164,685
-7,881
-5% -$161K ﹤0.01% 1717
2018
Q3 		$5.07M Sell
172,566
-7,848
-4% -$304K ﹤0.01% 1559
2018
Q2 		$8.2M Buy
180,414
+8,352
+5% +$406K 0.01% 1278
2018
Q1 		$9.09M Sell
172,062
-138,434
-45% -$8.08M 0.01% 1177
2017
Q4 		$21.1M Sell
310,496
-12,127
-4% -$848K 0.01% 767
2017
Q3 		$26.6M Buy
322,623
+3,245
+1% +$257K 0.02% 636
2017
Q2 		$29.9M Buy
319,378
+4,925
+2% +$301K 0.02% 601
2017
Q1 		$20M Buy
314,453
+41,383
+15% +$2.52M 0.01% 752
2016
Q4 		$12.1M Buy
273,070
+133,257
+95% +$4.69M 0.01% 1001
2016
Q3 		$5.04K Buy
139,813
+13,320
+11% +$286K ﹤0.01% 1611
2016
Q2 		$1.74M Buy
126,493
+13,873
+12% +$203K ﹤0.01% 2213
2016
Q1 		$2.16M Buy
112,620
+3,600
+3% +$76.2K ﹤0.01% 2023
2015
Q4 		$3.82M Sell
109,020
-3,191
-3% -$206K ﹤0.01% 1748
2015
Q3 		$10.3M Buy
112,211
+12,674
+13% +$1.1M 0.01% 1029
2015
Q2 		$8.75M Buy
99,537
+1,246
+1% +$107K 0.01% 1250
2015
Q1 		$7.3M Sell
98,291
-10,975
-10% -$775K 0.01% 1370
2014
Q4 		$6.12M Sell
109,266
-17,040
-13% -$896K ﹤0.01% 1478
2014
Q3 		$5.73M Sell
126,306
-1,834
-1% -$76.6K ﹤0.01% 1508
2014
Q2 		$5.31M Buy
128,140
+36,522
+40% +$1.88M ﹤0.01% 1654
2014
Q1 		$6.35M Sell
91,618
-1,322
-1% -$97.1K ﹤0.01% 1446
2013
Q4 		$5.6M Buy
92,940
+13,994
+18% +$761K ﹤0.01% 1558
2013
Q3 		$4.8M Buy
78,946
+11,976
+18% +$849K ﹤0.01% 1609
2013
Q2 		$4.49M Buy
+66,970
New +$3.01M ﹤0.01% 1610

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TIAA CREF Investment Management's CLVS Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Clovis Oncology, Inc. (CLVS) stake by 55% in Q1 2019, buying an estimated $2.27M and bringing the position to 255,289 shares worth $6.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

TIAA CREF Investment Management first reported a position in CLVS in Q2 2013 and has held it in 24 quarters since. The position peaked at $29.9M in Q2 2017. 186 funds tracked by Wall St. Rank hold CLVS as of Q1 2019.

  • TIAA CREF Investment Management held 255,289 shares of Clovis Oncology, Inc. worth $6.34M as of Q1 2019.
  • TIAA CREF Investment Management bought 90,604 Clovis Oncology, Inc. shares in Q1 2019, an estimated $2.27M.
  • Clovis Oncology, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1292 holding.
  • TIAA CREF Investment Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Clovis Oncology, Inc. position peaked at $29.9M in Q2 2017.
  • 186 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.